Patient safety

Patient safety is our focus

All of our products undergo thorough safety monitoring and evaluation processes at every stage of a medicine's lifecycle

Our Pharmacovigilance unit safety professionals are responsible for monitoring, identifying, analysing and reporting potential safety risks associated with the use of a Teva medicinal product or device.

Our pharmacovigilance team:

  • Takes an active part in the studies during the investigational stage, monitoring the safety of medicines in clinical use by collecting adverse events
  • Maintains an advanced database of all reported side effects that is used for effective collection, assessment and prevention of adverse events
  • Actively reviews and reports to regulatory authorities side effects reported by patients, their caregivers or healthcare professionals
  • Uses sophisticated techniques, data analytics and clinical judgment to determine the possibility of a new risk once a medicine is marketed
  • Is continuously monitored by regulatory authorities
  • Engages external advisory panels to ensure patient safety

How we collect safety data

Once a medicine has been released on the market, physicians, patients, healthcare teams and other caregivers can report side effects and safety concerns. All of our employees participate in pharmacovigilance training to ensure effective collection of safety data within our organisation.

Additionally, we take active measures to analyse all collected safety data:

  • Signal Detection - A periodic review, whereby the safety profile of each product is analysed and evaluated to identify any possible new safety issues
  • Periodic Safety Update Report - A comprehensive report submitted to the authorities that includes safety data and analysis of risk-benefit profile
  • Risk Management Plan - Based on a specific medicine’s safety profile, Teva suggests additional activities to monitor, minimise or prevent identified and potential risks and adverse events


FAQ about patient medication

FAQs for patients

Additional frequently asked questions about our medicines

Read more

Contact us

We're here to assist patients with information about our medicines, devices and services

Learn more

Share this article:

Date of preparation: April 2021
Reference: COB-IE-NP-00036